[Gene therapy and stem cell transplantation in PAD]

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Vascular Biology

Context:

• Peripheral artery disease (PAD) causes lower limb ischaemia, significantly impacting patient mobility and quality of life.
• Current treatments for severe PAD have limitations, creating a need for innovative therapeutic strategies.
• Therapeutic angiogenesis aims to restore blood flow by stimulating new blood vessel formation.

Purpose:

• To evaluate the safety and efficacy of plasmid-based fibroblast growth factor (FGF) gene therapy in patients with severe PAD.
• To assess the impact of FGF gene therapy on amputation rates and blood perfusion in ischaemic lower limbs.

Summary:

• Preliminary studies demonstrated the short-term safety and feasibility of gene therapy for therapeutic angiogenesis.
• The largest placebo-controlled trial to date involving plasmid-based FGF gene therapy in severe PAD patients showed significant reductions in amputation rates.
• While early reports on efficacy were inconclusive, this study provides compelling evidence for the effectiveness of angiogenic therapy.

Impact:

• The findings suggest that FGF gene therapy is a safe and effective treatment option for severe PAD, potentially reducing the need for amputation.
• This research lays the groundwork for larger clinical trials to further validate the efficacy of therapeutic angiogenesis in vascular disease.
• Successful therapeutic angiogenesis could revolutionize the management of ischaemic limb conditions, improving patient outcomes and limb salvage rates.